

AWARDS

Winners

- Marie Curie Award
- EANM Young Authors Award
- EANM Technologists Award
- EJNMMI Awards
- EANM Sanjiv Sam Gambhir Young Investigator Award

Year	City	Winner
------	------	--------

Patent Owner Exhibit 2124
IPR2025-01582

2023

Vienna

Molecular imaging predicts response absence to T-DM1 in advanced HER2-positive breast cancer: final results from a prospective phase II ZEPHIR trial

Mileva¹, E. G. de Vries², T. Guiot³, Z. Wimana⁴, A. Deleu¹, C. Schröder^{5,6}, Y. Lefebvre¹, M. Paesmans⁷, S. Stroobants⁸, M. Huizing⁹, P. Aftimos¹⁰, J. Tol¹¹, W. Van der Graaf¹², W. Oyen^{13,14,15}, D. Vugts¹⁶, C. Menke-van der Houven van Oordt¹², A. Brouwers¹⁷, M. Piccart-Gebhart¹⁰, P. Flamen¹, G. Gebhart¹;

¹Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ²Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, Groningen, NETHERLANDS, ³Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁴Department of Radiopharmacy, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁵Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, ⁶Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, NETHERLANDS, ⁷Data center, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, ⁸Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, ⁹Department of Medical Oncology, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, ¹⁰Department of Medical

Oncology, Institut Jules Bordet, Hôpital
Universitaire de Bruxelles (H.U.B), Université Libre
de Bruxelles (ULB), Brussels,
BELGIUM, ¹¹Department of Internal Medicine,
Jeroen Bosch Ziekenhuis, Den Bosch, the
Netherlands, Den Bosch,
NETHERLANDS, ¹²Department of Medical
Oncology, Amsterdam UMC location VUMC,
Cancer Centre Amsterdam, Amsterdam,
NETHERLANDS, ¹³Humanitas Clinical and Research
Center, Humanitas University, Milan,
ITALY, ¹⁴Department of Radiology and Nuclear
Medicine, Rijnstate Hospital, Arnhem,
NETHERLANDS, ¹⁵Department of Radiology and
Nuclear Medicine, Radboud University Medical
Center, Nijmegen, NETHERLANDS, ¹⁶Department
of Radiology and Nuclear Medicine, Amsterdam
UMC, Vrije Universiteit, Cancer Center Amsterdam,
Amsterdam, NETHERLANDS, ¹⁷Department of
Nuclear Medicine and Molecular Imaging,
University of Groningen, University Medical Center
Groningen, Groningen, NETHERLANDS.

2022

Barcelona

[¹⁸F]AlF-NOTA-octreotide vs. [⁶⁸Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial

E. Pauwels¹, F. Cleeren², T. Tshibangu², M. Koole¹, K. Serdons¹, L. Boeckxstaens¹, J. Dekervel³, T. Vandamme^{4,5}, W. Lybaert⁵, B. Van den Broeck⁶, P. M. Clement⁷, K. Geboes⁸, E. Van Cutsem³, S. Stroobants⁹, C. Verslype³, G. Bormans², C. M. Deroose¹;

¹Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, ²Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, ³Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM, ⁴Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM, ⁵Oncology, NETwerk Antwerpen-Waasland CoE, Antwerpen, BELGIUM, ⁶Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, ⁷General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM, ⁸Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM, ⁹Nuclear Medicine, Antwerp University Hospital; Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.

2021	Virtual	Enhanced Therapeutic Effect of the Albumin-Binding [^{177}Lu]Lu-Ibu-DAB-PSMA as Compared to [^{177}Lu]Lu-PSMA-617 – A Preclinical Therapy Study V. Tschan¹, F. Borgna¹, R. Schibli^{1,2}, C. Müller^{1,2}; ¹Paul Scherrer Institute, 5232 Villigen-PSI, SWITZERLAND, ²ETH Zurich, 8093 Zurich, SWITZERLAND.
2020	Virtual	Circulating androgen receptor gene amplification and resistance to ^{177}Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results of a phase 2 trial G. Paganelli¹, S. Severi¹, M. Sansovini¹, S. Nicolini¹, I. Grassi¹, F. von Eyben², V. Conteduca¹, M. Monti¹, F. Foca¹, G. Gurioli¹, M. Celli¹, F. Matteucci¹, U. De Giorgi¹; ¹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST IRCCS, Meldola (FC), ITALY, ²Center of Tobacco Control Research, Odense M, DENMARK.

2019

Barcelona

Changes in synaptic density in relation to tau deposition in prodromal Alzheimer's disease: a dual protocol PET-MR study

C. H. R. J. Vanhaute¹, J. Ceccarini², L. Michiels³, S. Sunaert⁴, R. Lemmens³, L. Emsell⁴, M. Vandenbulcke⁵, K. Van Laere²;

¹Nuclear Medicine and molecular imaging, Department of Geriatric Psychiatry, University Hospitals Leuven; department of imaging and pathology, Catholic University Leuven, Leuven, BELGIUM, ²Nuclear Medicine and molecular imaging, University Hospitals Leuven; department of imaging and pathology, Catholic University Leuven, Leuven, BELGIUM, ³Department of Neurology, University Hospitals Leuven; Laboratory for neurobiology, Catholic University Leuven; Center for Brain and disease research, VIB-KU Leuven, Leuven, BELGIUM, ⁴Department of Imaging and pathology, Translational MRI; Catholic University Leuven, Leuven, BELGIUM, ⁵Department of Geriatric Psychiatry, University Hospitals Leuven, Leuven, BELGIUM..

2018

Düsseldorf

Terblum-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer

C. Mueller¹, C. A. Umbricht¹, N. Gracheva¹, V. J. Tschan¹, G. Pellegrini², P. Bernhardt³, J. R. Zeevaart⁴, U. Koester⁵, R. Schibli¹, N. P. van der Meulen¹;

¹Paul Scherrer Institute, Villigen-PSI, SWITZERLAND, ²Vetsuisse Faculty, University of Zurich, Zurich, SWITZERLAND, ³University of Gothenburg, Gothenburg, SWEDEN, ⁴Necsa, Pretoria, SOUTH AFRICA, ⁵Insitut Laue-Langevin, Grenoble, FRANCE.

2017	Vienna	PSMA-targeting alpha-Radiation therapy with ^{225}Ac Actinium-PSMA-617: Dosimetry, toxicity and duration of tumor-control C. Kratochwil¹, F. Bruchertseifer², F. L. Giesel¹, C. Apostolidis², U. Haberkorn¹, A. Morgenstern²; ¹University Hospital Heidelberg, Heidelberg, GERMANY, ²EC-JRC, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY.
2016	Barcelona	Secondary glioblastoma multiforme – local alpha emitters targeted therapy with ^{213}Bi-DOTA-substance P L. Królicki¹, A. Morgenstern², J. Kunikowska¹, H. Koziara³, B. Królicki³, M. Jakuciński⁴, D. Pawlak⁵, C. Apostolidis², F. Bruchertseifer²; ¹ Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland, ² European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany, ³ Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, ⁴ Department of Nuclear Medicine, Brodnowski Hospital, Warsaw, Poland, ⁵ Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.
2015	Hamburg	Feasibility of Affibody molecule-based PNA-mediated pretargeting A. Honarvar et al., Uppsala University, Uppsala, SWEDEN.

2014	Gothenburg	Visualising Parasympathetic Denervation in Parkinson's Disease – [¹¹C]donepezil PET for Imaging Acetylcholinesterase Density in Peripheral Organs (Part I) P. Borghammer et al. Aarhus University Hospital, Aarhus, DENMARK.
2013	Lyon	A new route toward enhancing the uptake of [¹¹¹In/¹⁷⁷Lu-DOTA,Leu15]MS11 in ECK2R-positive xenografts in mice A. Kaloudi¹, B. A. Nock¹, E. Lymperis¹, P. J. Marsouvanidis^{1,2}, E. P. Krenning², M. de Jong^{2,3}, T. Maina-Nock¹; ¹Molecular Radiopharmacy, INRASTES, NCSR Demokritos, Athens, GREECE, ²Department of Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, ³Department of Radiology, Erasmus MC, Radiology, NETHERLANDS.

2012	Milan	Detection of prostate cancer using ^{68}Ga-labelled Bombesin analogue BAY 86-7548 in patients undergoing radical prostatectomy H. Minn^{2,5}, E. Kähkönen¹, I. Jambor^{2,3}, J. Kemppainen^{2,4}, K. Lehtiö⁵, J. Silén², A. Kuisma⁵, P. Luoto², T. Tolvanen², K. Alanen⁶, T. Grönroos², M. Kallajoki⁶, A. Roivainen², N. Schäfer⁷, R. Schibli⁸, M. Dragic⁸, A. Johayem⁹, R. Valencia¹⁰, S. Borkowski^{10,1} Department of Surgery, Division of Urology, Turku University Hospital, Turku, Finland, ²Turku PET Centre, University of Turku, Turku, Finland, ³Department of Diagnostic Radiology, University of Turku, Turku, Finland, ⁴Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland, ⁵Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland, ⁶Department of Pathology, Turku University Hospital, Turku, Finland, ⁷Department of Medical Oncology and Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland, ⁸Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland, ⁹Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland, ¹⁰Bayer Pharma AG, Berlin, Germany
2011 (http://www.eanm.org/congresses-events/cme-archive/cme-sessions-eam11)	Birmingham	Longitudinal imaging of transplanted islets in a rat model with SPECT K. Andralojc, M. Brom, L. Claessens-Joosten, D. Bos, W. Oyen, O. Boerman, M. Gotthardt; Radboud University & Medical Center Nijmegen, NETHERLANDS

2010	Vienna	VEGF Immuno-PET with ^{89}Zr-ranibizumab during sunitinib treatment M. N. Lub-de Hooge, W. B. Nagengast, J. A. Gietema, S. F. Oosting, M. A. de Korte, F. Warnders, H. Timmer-Boscha, G. A. Hospers, J. R. de Jong, W. F. den Dunnen, H. Hollema, R. A. J. O. Dierckx, E. G. E. de Vries; University Medical Center Groningen, Groningen, NETHERLANDS
2009	Barcelona	Development of an improved amyloid probe, [^{11}C]AZD2184. From pre-clinical to clinical in vivo PET measurements in AD patients J. Andersson¹, K. Varnäs¹, Z. Cselényi², B. Gulyás¹, B. Swahn³, S. Finnema¹, S. Nyberg², L. Farde², C. Halldin¹; ¹Karolinska Institutet, Stockholm, SWEDEN, ²AstraZeneca Pharmaceuticals Neuroscience Clinical, Södertälje, SWEDEN, ³Department of Medicinal Chemistry AstraZeneca R&D, Södertälje, SWEDEN
2008	Munich	Intravesical α-radioimmunotherapy with Bi-213-anti-EGFR-MAB defeats human bladder carcinoma in xenografted nude mice B. Pfof¹, C. Seidl¹, M. Autenrieth², D. Saur³, F. Bruchertseifer⁴, A. Morgenstern⁴, M. Schwaiger¹, R. Senekowitsch-Schmidtke¹ ¹Department of Nuclear Medicine, Technische Universität München, München, GERMANY, ²Department of Urology, Technische Universität München, München, GERMANY, ³II. Medizinische Klinik und Poliklinik, Technische Universität München, München, GERMANY, ⁴European Commission, JRC, Institute for Transuranium Elements, Karlsruhe, GERMANY

2007	Copenhagen	Converging evidence for specific neurotoxic effects of ecstasy on the thalamus: [123I]β-CIT SPECT and advanced MRI studies M. de Win et al. University Hospital Amsterdam, Amsterdam, The Netherlands
2006	Athens	Early predictive value of positron emission tomography with [18F]-fluorodeoxyglucose for the pathologic complete response of primary tumor in breast cancer patients treated by neoadjuvant chemotherapy A. Berriolo-Riedinger et al Centre G.F. Leclerc, Dijon, France
2005	Istanbul	A comparison of amphetamine induced changes in agonist and antagonist radioligand binding potential on the dopamine D2 receptor in primate brain N. Seneca, S. Finnema, M. Ichise, B. Gulyas, H. Wikstrom, R. Innis, L. Farde, C. Halldin (Stockholm, Bethesda, Groningen)
2004	Helsinki	^{99m}Tc Interleukin-2 (^{99m}Tc-IL2) Scintigraphy for Imaging Vulnerable Atherosclerotic Plaques A. Signore, A. Annovazzi, E. Bonnano, M. Arca, C. D'Alessandria, A. Marcocchia, L. Spagnoli, F. Violi, F. Scopinaro, G. De Toma (Rome)
2003	Amsterdam	Radioimmunotherapy with Lutetium-177-DOTA-Rituximab: a Phase I/II-Study in Patients with Follicular and Mantle Cell Lymphoma. An Interim Analysis F. Forrer, A. Lohri, H. Uusijärvi, G. Moldenhauer, J. Chen, R. Herrmann, E. Nitzsche, H. Mäcke, J. Müller-Brand (Basel, Liestal, Gothenburg)

2002	Vienna	Combined [¹¹C]Raclopride-PET and voxel based morphometry analysis in early Huntington's disease: separating between functional and morphological alterations F.D. Juengling, J. Karitzky, C. Solbach, J. Kassubek, C. Saft, B. Heinen, S.N. Reske, T. Kioschies, K. Henkel (Ulm)
2001	Naples	[¹¹C]MADAM – a highly suitable radioligand for examination of the serotonin transporter with PET C. Halldin, D. Guilloteau, J. Tarkiainen, J. Sóvágó, B. Gulyás, J. Sandell, P. Emond, J. Vercouillie, S. Chalon, J. Hiltunen, L. Farde
2000	Paris	Partial reversibility and gender differences in the toxic effects of MDMA ('ecstasy') on brain serotonin neurons L. Renemann, J. Booij, K. De Bruin, F.A. De Wolff, W. van den Brink, G.J. Den Heeten (Amsterdam)
1999	Barcelona	Low- versus high-dose radioimmunotherapy with humanized anti-CD20 antibodies in a broad spectrum of B-cell associated malignancies T.M. Behr, B. Wörmann, M. Gramatzki, M. Béhé, F. Griesinger, W. Hiddemann, D.M. Goldenberg, W. Becker (Göttingen)
1998	Berlin	Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer G. Paganelli, C. DeCicco, M. Cremonesi, A. Luini, M. Bartolomei, C. Grana, G. Proscio, V. Galimberti, P. Calza, G. Viale, U. Veronesi (Milan)

1997	Glasgow	Coronary revascularization improves survival and left ventricular function in patients with chronic coronary artery disease and dysfunctional but viable myocardium at thallium-201 imaging
		A. Cuocolo, E. Nicolai, M. Petretta, L. Pace, S. Cardei, A. Varrone, B. Trimarco, M. Salvatore (Naples)
1996	Copenhagen	Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter function assessed with I-123 IPT and SPECT
		K. Tatsch, P.D. Mozley, J. Schwarz, R. Linke, O. Pogarell, R.S. Fieber, K. Hahn, H.F. Kung (Munich)
1995	Brussels	Imaging of 5-HT1a receptors in human brain using (C-11)Way-100635 and PET
		V. Pike, J. McCarron, S. Hume, S. Ashworth, J. Opckajuffry, A. Lammerstma, K. Poole, A. Malizia, C. Bench, P. Grasby, I. Cliffe, A. Fletcher (London)
1994	Düsseldorf	Recombinant human interleukin-1: a potential agent to image infectious foci
		J. van der Laken, I.C. Boerman, W.J.G. Oyen, M.T.P. van de Ven, J. Makarewicz, R.A.M.J. Claessens, J.W.M. van der Meer, F.H.M. Corstens (Nijmegen)
1993	Lausanne	Comparison of 123-I-alpha-methyl tyrosine SPECT and 11C-L-methionine PET in patients with brain tumors: initial results
		K.J. Langen, B. Hamacher, K. Ziemons, T. Kuwert, U. Braun, H. Herzog, J.C.W. Kiwit, B. Nebeling, G. Stöcklin, H.W. Müller-Gärtner (Düsseldorf, Jülich)

1992	Lisbon	Preparation of $(11\text{C})\beta\text{-CIT}$, a new ligand for imaging cocaine binding sites in vivo by PET C. Halldin, L. Farde, L. Müller, P. Karlsson, J.L. Neumeyer, Y. Gao, R. Milius, H. Hall, C.G. Swahn (Stockholm, Natick)
1991	Vienna	PET studies of human cerebral malignancy with $(2\text{-}11\text{C})$ thymidine (TRD) and (18F) FDG T. van der Borght, S. Pauwels, L. Lambotte, L.D. Labor, S. De Maeght, G. Stroobandt, C. Laterre (Brussels)
1990	Amsterdam	Ventilation and perfusion in a single image J.J.P. de Lima, M.F.R. Botelho, A.M.S. Pereira, J.A.S. Rafael, M.A.T. Marques, A.J. Pinto, F. Godinho, M.C. Pereira, M.F. Baganha (Aveiro, Coimbra, Lisbon)

© European Association of Nuclear Medicine

Phone: +43 1 890 44 27 (tel:+4318904427) **E-mail:** office@eanm.org (mailto:office@eanm.org)